The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1293
Aliskiren/Hydrochlorothiazide (Tekturna HCT) for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Aliskiren/Hydrochlorothiazide (Tekturna HCT) for Hypertension
Aliskiren (Tekturna - Novartis), the first direct renin inhibitor for treatment of hypertension, has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide (Tekturna HCT - Novartis). Many angiotensin-converting enzyme...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aliskiren/Hydrochlorothiazide (Tekturna HCT) for Hypertension
Article code: 1293a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.